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E RYTHROMYCIN estolate, the lauryl sul-
fate salt of erythromycin 2-propio-
nate, has an advantage over erythromycin
base and erythromycin stearate in being
acid stable. After its introduction about
20 years ago, erythromycin estolate be-
came widely popular. Using conventional
methods of microbiologic assay, research-
ers found that oral administration of
the estolate produced higher total blood
levels of erythromycin than did en-
teric-coated erythromycin or propionyl
erythromycin and that food intake did
not affect these levels.’-8 It was presumed
that the apparent superiority of absorp-
tion of the propionate was the only rea-
son for these higher levels, but the as-
says used did not discriminate between
the bioactive and bioinactive portion of
plasma erythromycin.
In 1962, Griffith and Black9 showed
that similar peak blood levels resulted
from oral administration of a single 250.
mg dose of either erythromycin stearate
or erythromycin base protected by an
acid-resistant coating; however, adminis-
tration of 250 mg erythromycin estolate
resulted in levels almost four times those
obtained with the same dose of the base
or stearate salt. In 1964, Griffith and
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reported similar results from a
single- and multiple-dose study compar-
ing erythromycin estolate and erythro-
mycin stearate; blood levels of the esto-
late compared with those of the stearate
were at least twice as high in the fasting
state and more than 10 times higher in
the nonfasting state. In 1967, Bell”
found that erythromycin estolate pro-
duced higher blood levels than did an
enteric-coated preparation. (He also re-
ported later, in 1971, that serum levels
after administration of the estolate in
the nonfasting state were 14 times those
obtained after the same dose of the
stearate.’2)
It became evident, however, that only
a small proportion of erythromycin pro-
pionate was hydrolyzed in the blood-
stream after administration of erythro-
mycin estolate. Neaverson13 found in
1968 that the ratio of free erythromycin
to erythromycin propionate in the blood
was about 1:9. Using a different chro-
matographic procedure, Stephens et si.14
showed that the proportion of free base
was about 20 to 35 per cent of the total
antibiotic present in the blood. By 1969,
investigators were generally agreed that
erythromycin propionate is microbiologi-
cally inactive per se and must be hydro-
lyzed to its free base in order to exert
its antimicrobial action.’5
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The present study compares the plasma
concentrations of erythromycin base after
oral administration of erythromycin es-
tolate and enteric-coated erythromycin
base, using a newly developed chemical
method that discriminates between plasma
concentrations of erythromycin propion-
ate and erythromycin base.’6
MateriaLs and Methods
Subjects
Selected for the study were 16 normal,
healthy adult volunteers: six female
(average age, 23.5 years; average weight,
141.5 pounds) and 10 male (average
age, 20.7 years; average weight, 162.1
pounds). All were nonobese as deter-
mined by the criteria of Desirable
Weights of Adults’7 and had received no
antibacterial medication for 15 days, no
long-acting antibacterial drug for 30
days, and no other medication for seven
days before the start of the study. Tem-
perature, pulse, respiration, blood pres-
sure, and selected laboratory parameters
including hematologic findings, urinaly-
sis, blood urea nitrogen, serum alkaline
phosphatase, serum glutamic-oxaloacetic
transaminase, serum bilirubin, and glu-
cose all had to be within normal range.
Procedure
Subjects were given either a 250-mg
tablet of enteric-coated erythromycin5 or
a 250-mg capsule of erythromycin esto-
late** every 6 hours, with at least a 2-
hour fast before and after drug admin-
istration, for a total of 12 consecutive
doses. They drank 6 ounces water with
each dose.
A completely randomized two-way
crossover design was utilized, with seven
* E-Mycin, The Upjohn Company, Kalamazoo,
Mich. 49001, Lot Number 381CE, potency 262
mg.
** Ilosone, Dista Products Company, Indiana-
polis, Ind. 46206, Lot Number 7FJ75A, potency
259 mg.
days separating the initial medication
days for the two treatment periods. The
subjects were confined the night before
the study started and for the entire 84
hours of each treatment period. They re-
ceived standardized meals, ingesting each
within a 30-minute interval. The sched-
ule for meals and medication was as fol-
lows: minus 2.5 hours, breakfast; 0
hours, dose #1; 3.5 hours, lunch; 6
hours, dose #2; 8.5 hours, dinner; 12
hours, dose #3; 15.5 hours, snack; 18
hours, dose #4; 21.5 hours, breakfast; 24
hours, dose #5. This pattern was repeated
until the administration of dose #12 at
66 hours.
Subjects were permitted to smoke but
not to engage in any strenuous or athletic
activities during the days of or on the
day following drug administration. Blood
samples were drawn from each subject at
1.5-hour intervals during the first 12
hours of day 1 (0-12 hours after the first
dose), every 1.5 hours on day 3 (48-72
hours after the first dose), and every 4
hours thereafter until the 84th hour. This
allowed for sampling of the last dose up
to 18 hours after administration. Plasma
was harvested from all blood samples
right after drawing and was frozen im-
mediately.
Analysis of Plasma Samples
Investigators analyzed erythromycin
in the plasma samples by the method of
Tserng and Wagner.’6 Since hydrolysis
of propionyl erythromycin is appreciably
slower in the frozen state than in solu-
tion, appropriate corrections were made
for continued hydrolysis. Plasma levels
of erythromycin base and erythromycin
propionate were measured separately in
each sample from all subjects who re-
ceived erythromycin estolate. The total
erythromycin plasma level is defined as












Fig. 1. Average plasma erythromycin concentrations (in pg/mi) from
16 healthy subjects after 12 250-mg doses of erythromycin enteric-
coated tablets or erythromycin estolate capsules, given every 6 hours
with a 2-hour fast before and after: (.) erythromycin enteric-coated
tablet (Lot #381CE); (#{149})erythromycin estolate capsule (Lot
#7FJ7SA); (A) erythromycin estolate capsule (Lot #7FJ75A) as




Data were analyzed according to the
standard analysis of variance for equally





As anticipated, total erythromycin lev-
els (erythromycin base plus erythro-
mycin propionate) after administration
of erythromycin estolate capsules were
at least three times higher than those
after administration of erythromycin en-
teric-coated tablets. The average plasma
erythromycin and total erythromycin
concentration-time profiles obtained with
both treatments are presented in Fig. 1.
A comparison of the plasma total erythro-
mycin levels at each sampling time and
parameters of maximum concentration,
minimum concentration, and area un-
der the plasma concentration-time curve
tested significantly different (P < 0.001)
for the two preparations. These findings
are in agreement with earlier studies
which used microbiological assay.10-
Comparison of Erythromycin
Plasma Levels
After three days of oral administra-
tion of erythromycin estolate, the per
cent hydrolysis of erythromycin pro-
pionate to erythromycin base averages
about 24 per cent, ranging from a low
of 16 per cent 3 hours after the first dose
to a high of 43 per cent 18 hours after
administration of the 12th, or last, dose.
(The 43 per cent figure is probably due
to assay insensitivity at the low concen-
trations occurring 18 hours after the last
dose.) Disregarding the data beyond 72
hours, the range in hydrolysis would
vary from the 16 per cent low (occur-
ring 3 hours after the first dose) to a
high of 27 per cent, which occurred at
6, 55.5, 66, and 72 hours after drug ad-
ministration.
As illustrated in Fig. 1, there were
minimal differences in the amount of bio-





Multiple-Dose Bioavailability Parameters Obtained for 16 Normal Adults Following
Oral Administration of 12 Consecutive Doses of 250 mg Erythromycin
in a Multiple-Dose Regimen*
Dosing Erythromycin Erythromycin Statistical
interval enteric-coated estolate significance
(hr) tablet capsule (ANOVA)













Average of the individual
maximum serum concentration
(pg/mi) at
Average of the individual
minimum serum concentration
(pg/ml) at
Average of areas under
individual serum concentration-




3rd Day (48-84 Hours; 9th-12th Doses)
48-54 1.89 1.36 P < 0.025
54-60 1.40 1.37 u.s.
60-66 1.32 1.21 n.s.
66-72 1.86 1.36 u.s.
66-84 2.08 1.38 P < 0.05
48-54 0.68 0.57 u.s.
54-60 0.54 0.70 u.s.
60-66 0.48 0.70 P < 0.025
66-72 0.34 0.75 P < 0.005
66-84 0.20 0.16 n.s.
48-54 7.67 5.61 P < 0.025
54-60 5.67 6.25 u.s.
60-66 5.20 5.66 n.s.
66-72 5.55 6.30 u.s.
66-84 14.81 11.68 n.s.
48-72 24.10 23.83 u.s.
48-84 33.36 29.21 u.s.
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Average of the individual
maximum serum concentration
(pg/mi) at
Average of the individual
minimum serum concentration
(pg/mi) at
Average of areas under
individual serum concentration-
time curves (pg. hr/nil) at
* Erythromycin base, 250.mg enteric-coated tablet;
tion of either erythromycin base enteric-
coated tablets or erythromycin estolate
capsules. Of the 28 average plasma
erythromycin concentration values ob-
tained, six showed significant differences
(P < 0.05 or better) in base concentra-
or erythromycin estolate, 250-mg capsule.
tions for the two treatments, with higher
levels generated by the enteric-coated
tablets at 3, 49.5, 51, 80, and 84 hours
and by the estolate capsules at 69 hours.
Table I lists for each dosing interval






0 0.01-0. 0.20- 0.51- 0.76- 1.01- 1.26- 1.51- 1.76- 2.01- 2.20- 2.51
0.50 0.76 1.00 1.26 1.60 1.76 2.00 2.20 2.60
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centrations and areas under the concen-
tration-time curve (AUCs). The average
erythromycin AUC during 0 to 12 hours
on the first day of drug administration
was 7.48 g . hr/ml for erythromycin en-
teric-coated tablets and 6.76 g hr/mi
for the erythromycin estolate capsules.
The area generated during 48 to 72 hours
(day 3) was 24.1 jg hr/ml for the tab-
lets and 23.83 g hr/mi for the capsules.
Averages of the individual maximum
erythromycin plasma concentrations oc-
curring during all dosing intervals were
higher with erythromycin base enteric-
coated tablets than with erythromycin
estolate capsules. At 0 to 6 hours and 6
to 12 hours, the average maximum con-
centrations, in g/ml, with the base tab-
lets were 1.17 and 1.34, respectively; dur-
ing the same intervals, the estolate cap-
sules gave average maximum concentra-
tions of 0.73 and 1.27 g/ml, respectively.
On day 3, maximum concentrations be-
tween 48 and 54 hours and 66 and 84
hours were 1.89 and 2.08 g/inl, respec-
tively, for the erythromycin enteric-coated
tablets and 1.36 and 1.38 g/ml, respec-
tively, for the erythromycin estolate cap-
sules. These differences were statistically
significant.
Averages of the individual minimum
concentrations tended to be slightly lower
with the enteric-coated tablets than with
the estolate capsules. However, the differ-
ences were not statistically significant ex-
cept after the third and fourth doses on
day 3, when minimum concentrations
were 0.48 and 0.34 g/ml, respectively,
for the tablets, compared with 0.70 and
0.75 g/ml, respectively, for the capsules.
Figure 2 delineates for each form of
the drug the percentage of plasma sam-
ples found to contain specific concentra-
tions of erythromycin base during the
four steady-state dosage intervals from
48 to 72 hours. As this histogram shows,
there are minimal differences between the
levels obtained with tablets or capsules.
Discussion
In the early 1960s, investigators18’9
showed by means of a microbiologic assay
method employing Sarcina lutea that se-
rum levels of total erythromycin after
Fig. 2. Percentage of plasma samples with specific concentrations of
erythromycin base during four steady-state dosage intervals (48-72
hours) after administration of 250-mg doses given every 6 hours:
(.) erythromycin enteric-coated; (0) erythromycin estolate.
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administration of erythromycin estolate
are superior to those obtained with eryth-
romycin. Later, Tserng and Wagner16 dis-
cussed factors that must be considered in
evaluating serum concentrations of eryth.
romycin by microbiologic assay. Stephens
et al.,15 using paper chromatography, had
shown in 1969 that the major circulating
species after administration of erythro-
mycin estolate was erythromycin propio-
nate, with whole blood, serum, plasma,
and urine containing 20 to 25 per cent
erythromycin and 75 to 80 per cent eryth-
romycin propionate. The results of the
present study agree quite well with these
findings.
Apparently, 75 per cent of the erythro-
mycin propionate is hydrolyzed to bio-
active erythromycin base during the mi-
crobiologic assay process itself. In this
study it also has been shown that the per
cent total erythromycin propionate hy-
drolyzed to erythromycin is relatively
constant from dose to dose. Bechtol and
co-workers2’ did not find this consistency
in in vivo hydrolysis; they reported that
erythromycin propionate undergoes more
hydrolysis after multiple doses than after
a single dose. (Their results showing an
increase in hydrolysis on continued dosing
was probably due to methodologic errors
which they reported.)
Although the efficiency of gastrointes-
tinal absorption of erythromycin propio-
nate is apparently greater than that of
erythromycin, the results of this study
show that there is essentially no differ-
ence in the circulating levels of bioactive
erythromycin base after administration of
either enteric-coated base tablets or esto-
late capsules.
Summary
A randomized crossover study in 16
healthy volunteers given multiple doses
of erythromycin base enteric-coated tab-
lets or erythromycin estolate capsules re-
vealed essentially no difference in the
resultant plasma concentration of bioac-
tive erythromycin. This similarity in bio-
activity persisted despite the fact that
total erythromycin levels (bioactive eryth.
romycin base plus bioinactive erythro-
mycin propionate) were at least three
times higher after administration of the
estolate than after administration of the
base.
Acknowledgment
The authors wish to acknowledge the assis-
tance of Diane Langkamp in the preparation
of this manuscript.
References
1. Hirsch, H. A. and Finland, M.: Effect of
food on the absorption of erythromycin
propionate, erythromycin stearate and tn-
acetyloleandomycin. Am. J. Med. Boi.
237:693 (1959).
2. Blough, H. A., Hall, W. H., and Hong, L.:
Serum levels and clinical results with
erythromycin propionate. Amer. J. Med.
Sci. 239:539 (1960).
3. Clapper, W. E., Mostyn, M., and Meade,
G. H.: An evaluation of erythromycin
stearate and propionyl erythromycin in
normal and hospitalized subjects. Ants-
biot. Med. Clin. Therap. 7:91 (1960).
4. Quinn, E. L., Colville, J. M., and Cox, F.:
Comparative studies of erythromycin pro.
pionate, erythromycin stearate, and tn-
acetyloleandomycin. Antibiotic. Med. Chn.
Therap. 7:103 (1968).
5. Hall, G. A., Roberts, C. E., Perry, D. M.,
and Kirby, W. M. M.: Erythromycin stear-
ate and propionyl erythromycin: A com-
parison of blood levels obtained after
oral administration. Antibiot. Med. GUn.
Therap. 7:231 (1960).
6. Perry, D. M., Hall, G. A., and Kirby,
W. H. H.: Clinical and laboratory studies
of erythromyciu propionate. Antibiot.
Med. GUn. Therap. 7:320 (1960).
7. Griffith, R. S.: Comparison of antibacterial
activity in the sera of subjects ingesting
erythromycin and propionyl erythromycin
lauryl sulfate. Antimicrob. Agents Ann.
192 (1960).
8. Hirsch, H. A., Pryles, C. V., and Finland,
M.: Effect of food on absorption of a
new form of erythromycin propionate.
Amer. J. Med. Sci. 239:198 (1960).
9. Griffith, R. S. and Black, H. B.: A com-
parison of blood levels after oral admin-
istration of erythromycin and erythro-




10. Griffith, B. S. and Blank, H. B.: Compari-
son of the blood levels obtained after
single and multiple doses of erythromycin
estolate and erythromycin stearate. Amer.
.1. Med. Sci. 247:69 (1964).
11. Bell, S. and Lake, B.: Crossover blood level
studies with erythromycin estolate and a
“new” erythromycin. Med. J. Au8t. 1:1152
(1967).
12. Bell, S. M.: A comparison of absorption
after oral administration of erythromycin
estolate and erythromycin stearate. Med.
J. Aust. 2:1280 (1971).
13. Neaverson, M. A.: Erythromycin estola.te.
Med. J. Aust. 1:741-742 (1968).
14. Stephens, V. C., Pugh, C. T., Davis, N. E.,
Hoehn, M. M., Ralston, S., Sparks, M. C.,
and Thomkins, L.: A study of the be-
havior of propionyl erythromycin in blood
by a new chromatographic method. J.
Antibiotics 22:551 (1969).
15. Tardrew, P. L., Mas, J. C. H., and Kenney,
D.: Antibacterial activity of 2-esters of
erythromycin. App1. Micro. 18:159 (1969).
16. Tserng, K., and Wagner, J. G.: Fluoromet-
ne determination of erythromyein and
erythromyein propionate in whole blood
or plasma and correlation of results with
microbiological assay. J. Anal. Chem.
48:348 (1976).
17. Scientific Tables Documents, 6th Ed., Geigy
Pharmaceuticals, Div. of CIBA.Geigy
Corp., Ardsley, N.Y. p. 624.
18. Kavanagh, F., and Dennin, L. J.: In Ana-
lytical Microbiology, F. Kavanagh, Ed.
Academic Press, New York 1963, p. 289.
19. Grove, D. C., and Randall, W. A.: Assay
Methods of Antibiotics: A Laboratory
Manual. New York, Medical Encyclopedia,
1955.
20. Weigand, B. G., and Chun, A. H.: Serum
Protein Binding of Erythromycin and
Erythromycin 2’-Propionate Ester. 1.
Pharm Sci. 61:425 (1972).
21. Beehtol, L. D., Stephens, V. C., Pugh, C. P.,
Perkal, M. B., and Coletta., P. A.: Ery-
thromycin Esters-Comparative in-Vivo
Hydrolysis and Bioavailability. Cswr.
Therap. Res. 20:610 (1976).
Address reprint requests to: Dr. A. B. DiSanto,
The Upjohn Company, Kalamazoo, Mich. 49001.
